Aspen pockets R2bn profit as it offloads European rights to HRT drug

Aspen Pharmacare’s shares rose 2% on Monday after it announced the sale of the European rights to its menopause-treatment brand Ovestin for R3.7 billion, booking a R2 billion profit.

— News24 Business
Read the full story on News24 Business

This story was written and published by News24 Business. Business.co.za shows its headline and teaser from the publisher’s RSS feed and links to the original.

What business people are saying

0

No comments yet. Be the first.

More in Markets & investing

All →